Clinical trials
Relapsed or Refractory Plasma Cell Neoplasms clinical trials
Below are recruiting relapsed or refractory plasma cell neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,654 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+ - NCT07174661Recruiting
Planning ahead for teens and young adults with advanced cancer
This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.
Scottsdale, ArizonaAges 18–39 - NCT07148050RecruitingPhase 1
CAR T-cell therapy for children with solid tumors
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
Seattle, WashingtonAges 1–26 - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07052305RecruitingPhase 1
Testing NT-I7 after CAR T-cell therapy for large B-cell lymphoma
This trial tests whether a drug called NT-I7 (efineptakin alfa) can help people with large B-cell lymphoma who have already received a CAR T-cell treatment like Yescarta or Breyanzi. It aims to boost your immune system's recovery and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06976437RecruitingEarly Phase 1
Testing donor CAR-T cells for B-cell blood cancers
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Zhenjiang, JiangsuAges 18 years+ - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06815029RecruitingPhase 1
Modified immune cells for recurrent brain cancer
This trial tests a new treatment using your own immune cells that are genetically modified to find and attack brain tumor cells. It is for people with a type of brain cancer that has come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06768905RecruitingPhase 1/Phase 2
Radiation followed by CAR-T cells for relapsed/refractory DLBCL
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
Dallas, TexasAges 18 years+ - NCT06430424Recruiting
Study of body markers in recurrent glioblastoma
This study looks at special markers in the blood and tumors of people whose glioblastoma has come back. It may help doctors understand why the cancer returns and how to treat it better.
BordeauxAges 18 years+ - NCT06742996RecruitingPhase 3
Sonrotoclax plus zanubrutinib for relapsed mantle cell lymphoma
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Birmingham, AlabamaAges 18 years+ - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT06699771RecruitingPhase 1
Safety study of GCC2005 for NK and T-cell cancers
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Seoul, SeoulAges 19–80 - NCT06696846RecruitingPhase 1
CAR-NK cell therapy for T cell lymphoma and acute myeloid leukemia
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06625190RecruitingPhase 1/Phase 2
Half-matched transplant with zoledronic acid for resistant solid tumors
This trial tests a new approach using a special type of transplant (with cells from a half-matched family donor) plus a drug called zoledronic acid. It is for children and young adults with certain solid tumors that have not responded to standard treatments.
Gainesville, FloridaAges 6 months–25 years - NCT06569082Recruiting
Stem cell boost for poor graft function
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
New York, New YorkAges 18 years+ - NCT06553898RecruitingPhase 1
CAR-T cell therapy for hard-to-treat kidney disease
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
Hangzhou, ZhejiangAges 2 years+ - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06536257Recruiting
Personalized immunotherapy prediction for melanoma and other cancers
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Sydney, New South WalesAges 18 years+ - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06526793RecruitingPhase 2
Surovatamig for relapsed or refractory B-cell lymphoma
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Phoenix, ArizonaAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
New Haven, ConnecticutAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory plasma cell neoplasms?
- Yes. Clin2 currently lists 1,654 recruiting relapsed or refractory plasma cell neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory plasma cell neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory plasma cell neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Refractory Plasma Cell Myeloma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.